Christian Rutzer, Deputy Head and Lead Scientist at the CIEB University of Basel, shared on LinkedIn:
“𝐑𝐨𝐜𝐡𝐞 𝐚𝐧𝐝 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬: 𝐁𝐚𝐬𝐞𝐥’𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 and 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐏𝐨𝐰𝐞𝐫𝐡𝐨𝐮𝐬𝐞𝐬
Both research and innovation (R and I) are key drivers of a successful drug pipeline. With this in mind, we at the CIEB Universität Basel analyzed the quality of large pharmaceutical companies’ R&I activities. Here are our key findings:
– Basel-based Roche is very strong in R adn I, as evidenced by a much higher than average number of citations per scientific paper and patent. Basel-based Novartis is also above average on both counts.
– Amgen, Gilead Sciences, Astra Zeneca, and Bristol Myers Squibb also have both highly cited scientific papers and patents. Amgen in particular has received many citations for its patents.
– Novo Nordisk, Pfizer, Bayer, and Glaxo Smith Kline have highly cited scientific papers but not as many highly cited patents.
In summary, our analysis confirms that Basel-based Roche and Novartis are among the leaders in producing highly cited and influential R and I. These results point to a positive future for Basel in drug development and healthcare innovation.
Notes: Data include company affiliations. For example, Genentech is assigned to Roche. We used all USPTO patents and scientific papers from the Scopus database attributed to the pharmaceutical field between 2013 and 2022. For patents, we used docdb family citations, and for papers, we weighted citations by author (as papers often contain a larger number of authors from different institutions).”
Source: Christian Rutzer/LinkedIn